The U.S. Food and Drug Administration granted marketing authorization for the first home-based, nonprescription diagnostic ...
Medical Device Network on MSN1d
FDA authorises Visby Medical’s at-home test for common STIsThe US Food and Drug Administration (FDA) has authorised the first at-home PCR STI test for chlamydia, gonorrhoea, and ...
President Trump’s FDA Grants Marketing Authorization of First Home Test for Chlamydia, Gonorrhea and Trichomoniasis ...
The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.
Visby Medical’s at-home diagnostic, which can be purchased without a prescription, tests for chlamydia, gonorrhea and ...
This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.
The US Food and Drug Administration (FDA) granted marketing authorization to Visby Medical for the Visby Medical Women’s Sexual Health Test. This is the first diagnostic test for chlamydia, gonorrhoea ...
The Food and Drug Administration (FDA) has cleared the Visby Medical Women’s Sexual Health Test for use at home to test for ...
The FDA on Friday granted marketing authorization to the first at-home test for diagnosing chlamydia, gonorrhea, and ...
The U.S. Food and Drug Administration (FDA) has granted marketing authorization to Visby Medical for its Women’s Sexual Health Test, the first home diagnostic test for chlamydia, gonorrhea, and ...
As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback